Corbus Pharmaceuticals Holdings, Inc.

CRBP Healthcare Biotechnology

In the quarter to June 2026, EPS fell 25.7% and free cash flow fell 78.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.52 0.19 +4.39%
Market cap
$83.8M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
3/9
Altman Z
−4.15
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.31 8.07 7.92 5.71
Net Debt/EBITDA
4.27 7.25 5.63 3.24
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.26) (1.20) (1.37) (1.53)
Book value per Share
7.49 11.08 6.75 5.27
Free Cash Flow
(15.55) (15.93) (25.58) (29.63)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates